Compare Neurocrine Biosciences Inc (NBIX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Charles Schwab Corporation Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B), while Charles Schwab Corporation Common Stock trades at $96.74 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 11.7× Neurocrine Biosciences Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| NBIX | SCHW | |
|---|---|---|
Market Cap | $14.36B | $167.52B |
Volume | 1,237,180 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $185.50 | $113.65 |
52-Week Low | $123.10 | $85.35 |
Typical Hold Time | 23 Days | 85 Days |
Enterprise Value | $14.37B | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Charles Schwab (SCHW) trades at $95.58, down 1.26% today, amid bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.62 exceeding expectations of $1.56, while revenue grew to $23.92B in 2025. Analyst consensus remains bullish with a $119.92 price target, though technical indicators show selling pressure with RSI at oversold levels and bearish moving average alignment.
SCHW presents a compelling value opportunity with attractive valuation metrics (P/E 17.64) and robust profitability (ROE 22.45%), but faces near-term technical headwinds and market volatility risks. The company's expansion into AI integration and Texas Stock Exchange listing provides growth catalysts, though investors should monitor interest rate sensitivity and competitive pressures in the brokerage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
